This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celgene's Abraxane Under Fire in NEJM Letter

Memorial Sloan-Kettering Cancer Center oncologist Dr. Leonard Saltz has become a vocal and effective critic of pharmaceutical companies marketing cancer drugs which cost too much and benefit patients too little. Last year, Saltz co-authored an op-ed in the New York Times, in which he said Sloan-Kettering was refusing to use the Sanofi (SNY - Get Report) colon cancer drug Zaltrap because it was twice as expensive but no more effective than Roche's Avastin. Sanofi bowed to the pressure, cutting the price of Zaltrap in half. 

Saltz has now taken aim at another drug -- Celgene's (CELG - Get Report) Abraxane, which was recently approved for the treatment of pancreatic cancer and is also approved for breast and lung cancer.

Saltz and colleague Dr. Peter Bach penned a letter published in this week's New England Journal of Medicine, raising concerns about the risk-benefit of Abraxane relative to the added cost of its use in pancreatic cancer patients. 

Here's the full text of the Saltz-Bach letter (nab-Paclitaxel is the scientific name for Abraxane):

The article by Von Hoff et al. (Oct. 31 issue)1 is entitled "Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine." This title strikes us as inappropriately rosy, given the modest benefits and substantial toxic effects observed. The addition of nab-paclitaxel increased the median survival by 1.8 months, or 55 days. The chance of being alive at 2 years was increased from 4% to 9%. Meanwhile, an additional 10% of patients had grade 3 (severe) fatigue. Grade 2 fatigue (moderate, not relieved by rest) and duration of fatigue are not mentioned. Grade 3 (severe) neuropathy was increased by 16%. No data on grade 2 (moderate) neuropathy are presented. No data on the out-of-pocket costs of the nab-paclitaxel are provided, even though negative financial consequences represent another source of "toxicity" and a driver of bankruptcies. In this study, the incremental cost of nab-paclitaxel was around $25,000 on the basis of Medicare reimbursement rates. A more neutral title, such as "Nab-Paclitaxel plus Gemcitabine in Pancreas Cancer," might help avoid an imbalanced perception of the study findings.

Also in this week's NEJM, Dr. Daniel Von Hoff and his colleagues, authors of the Abraxane pancreatic cancer study, respond:

The authors reply: In response to Saltz and Bach: the benefit of therapy with nab-paclitaxel plus gemcitabine needs to be evaluated in the context of innovations for advanced pancreatic cancer and other cancer treatments. Since 1997, more than 30 large trials involving patients with pancreatic cancer have been conducted, and only 3 have shown a statistically significant improvement in survival, as compared with gemcitabine alone. The survival curves in our study separate early and continue to diverge. It is important to note that the rate of long-term survival was increased at 1 year (35% vs. 22%) and beyond. Our relative increase in median survival of 26.9% (hazard ratio, 0.72) is similar to results observed in studies that led to drug approvals by the Food and Drug Administration from January 2009 through November 2013 across nine tumor types, with a mean hazard ratio of 0.70 (range, 0.44 to 0.82) and a mean relative increase in median survival of 27.6% (range, 14.3 to 67.2).

The rates of grade 1 or 2 fatigue with the combination therapy were increased by 5 percentage points, from 36% to 41%. A detailed analysis of neuropathy was presented, showing that grade 2 occurred in 14% of patients and grade 3 in 17% of patients, predominantly late in their treatment. For patients who received the average 4 months of treatment, rates of grade 2 and grade 3 neuropathy were 6% and 7%, respectively. Neuropathy was rapidly reversible, and for nearly half the patients, treatment resumed after interruption. On that basis, this regimen can be built on as the backbone for combinations to enhance this initial advance.

For the incremental treatment cost, analyses must be viewed in the context of the total cost of care, including drugs, drug administration, growth factors, supportive care, and duration of illness. To address these factors, a pharmacoeconomic analysis of this complex multinational study is needed. The cited Washington State study involving cancer patients in which younger patients with local disease were at increased risk for bankruptcy is less relevant for patients with metastatic pancreatic cancer, in whom the median age at diagnosis is more than 70 years.

Celgene said Abraxane sales in 2013 totaled $649 million, a 52% year-over-year increase. The company does not break out Abraxane sales by cancer indication. 

Saltz doesn't appear to be a fan of Abraxane in pancreatic cancer but then, he says nothing about eliminating its use at Sloan Kettering in his NEJM letter, either. Saltz's criticism of Abraxane is another reminder, however that the controversy over drug pricing and reimbursement isn't going anyway.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs